this out just s few min ago:
(COMTEX) B: CompuMed Announces Favorable Clinical Trial Results for t
B: CompuMed Announces Favorable Clinical Trial Results for the Automated
OsteoGram(R)
LOS ANGELES, Apr 11, 2000 /PRNewswire via COMTEX/ -- CompuMed, Inc. (OTC
Bulletin Board: CMPD.OB) announced today favorable results of the clinical
trials evaluating its phalangeal bone mineral density software, the Automated
OsteoGram(R).
CompuMed has concluded the preliminary analysis phase of the clinical trials
conducted in January and February of 2000 using the Automated OsteoGram(R). The
study included approximately 200 female volunteers between the ages of 20 and 79
and aimed at assessing phalangeal bone mineral density using two x-ray methods,
direct exposure and screened exposure (acquired with common intensifying
screens). The results showed a very high correlation between the two methods.
"The latest beta testing feedback and current clinical trial results assure that
the Automated OsteoGram(R) is a reliable tool for assessing bone mineral
density. We are very pleased with the conclusion of these studies and look
forward toward a successful launch of our product in the very near future,"
stated Robert B. Goldberg, Chairman and CEO of CompuMed.
CompuMed, based in Los Angeles, California, develops solutions to important
medical problems through the use of computer technology. In addition to the
Automated OsteoGram(R), CompuMed has developed and is marketing computer-aided
telemedicine services for cardiology and currently provides on-line computer
interpretation of electrocardiograms (ECG's) to physicians, government and
corporate healthcare providers.
This news release contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future events or
performance and underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to uncertainties
and risks including, but not limited to, product and service demand and
acceptance, changes in technology, ability to raise capital, the availability of
appropriate acquisition candidates and/or business partnerships, economic
conditions, the impact of competition and pricing, capacity and supply
constraints or difficulties, government regulation and other risks defined in
this document. All such forward-looking statements whether written or oral, and
whether made by or on behalf of the Company are expressly qualified by these
cautionary statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims any
obligation to update any forward-looking statements to reflect events or
circumstances after the date hereof.
SOURCE CompuMed, Inc.
(C) 2000 PR Newswire. All rights reserved.
prnewswire.com
-0-
CONTACT: Robert B. Goldberg, Chairman and Chief Executive Officer of
CompuMed, Inc., 310-258-5000, ext. 115; or Media, Kristen Ham
er of
Noonan-Russo Communications, Inc., 212-696-4455, ext. 249,
news@noonanrusso.com, for CompuMed, Inc.
KEYWORD: California
INDUSTRY KEYWORD: MTC
BIO
SUBJECT CODE: OTC
URL: compumed.net
*** end of story *** |
